Morgan Stanley Vaxart, Inc. Transaction History

Morgan Stanley

$1.36 Trillion
Q1 2025

A detailed history of Morgan Stanley transactions in Vaxart, Inc. stock. As of the latest transaction made, Morgan Stanley holds 214,028 shares of VXRT stock, worth $85,611. This represents 0.0% of its overall portfolio holdings.

Number of Shares

214,028

Previous 106,725 100.54%

Holding current value

$85,611

Previous $70,000 24.29%

% of portfolio

0.0%

Previous 0.0%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	BUY	$0.41 - $0.94 $43,994 - $100,864	107,303 Added 100.54%	214,028 $87,000
Q4 2024 Feb 14, 2025	BUY	$0.54 - $0.86 $6,501 - $10,353	12,039 Added 12.71%	106,725 $70,000
Q3 2024 May 14, 2025	BUY	$0.58 - $0.99 $796 - $1,359	1,373 Added 1.47%	94,686 $80,000
Q3 2024 Nov 14, 2024	BUY	$0.58 - $0.99 $796 - $1,359	1,373 Added 1.47%	94,686 $80,000
Q2 2024 May 14, 2025	SELL	$0.53 - $1.3 $7,108 - $17,435	-13,412 Reduced 12.57%	93,313 $62,000
Q2 2024 Oct 17, 2024	SELL	$0.53 - $1.3 $98,027 - $240,445	-184,958 Reduced 66.47%	93,313 $62,000
Q2 2024 Aug 14, 2024	SELL	$0.53 - $1.3 $98,027 - $240,445	-184,958 Reduced 66.47%	93,313 $62,000
Q1 2024 Oct 17, 2024	BUY	$0.56 - $1.41 $103,576 - $260,790	184,958 Added 198.21%	278,271 $361,000
Q1 2024 Aug 16, 2024	SELL	$0.56 - $1.41 $51,490 - $129,645	-91,947 Reduced 24.84%	278,271 $361,000
Q1 2024 May 15, 2024	SELL	$0.56 - $1.41 $51,490 - $129,645	-91,947 Reduced 24.84%	278,271 $361,000
Q4 2023 Aug 16, 2024	BUY	$0.57 - $0.85 $157,835 - $235,369	276,905 Added 296.75%	370,218 $211,000
Q4 2023 Feb 13, 2024	SELL	$0.57 - $0.85 $23,302 - $34,748	-40,881 Reduced 9.94%	370,218 $211,000
Q3 2023 Nov 15, 2023	SELL	$0.69 - $0.85 $26,889 - $33,124	-38,970 Reduced 8.66%	411,099 $308,000
Q2 2023 Aug 14, 2023	SELL	$0.6 - $1.41 $31,723 - $74,549	-52,872 Reduced 10.51%	450,069 $328,000
Q1 2023 May 15, 2023	SELL	$0.71 - $1.25 $94,509 - $166,390	-133,112 Reduced 20.93%	502,941 $382,000
Q4 2022 Feb 14, 2023	BUY	$0.75 - $2.24 $23,166 - $69,191	30,889 Added 5.1%	636,053 $610,000
Q3 2022 Nov 14, 2022	SELL	$2.09 - $4.5 $1.17 Million - $2.52 Million	-560,323 Reduced 48.08%	605,164 $1.32 Million
Q2 2022 Oct 27, 2022	SELL	$2.7 - $5.28 $235,769 - $461,060	-87,322 Reduced 6.97%	1,165,487 $4.08 Million
Q2 2022 Aug 15, 2022	SELL	$2.7 - $5.28 $235,769 - $461,060	-87,322 Reduced 6.97%	1,165,487 $4.08 Million
Q1 2022 Oct 27, 2022	BUY	$4.29 - $6.64 $374,611 - $579,818	87,322 Added 7.49%	1,252,809 $6.31 Million
Q1 2022 May 13, 2022	BUY	$4.29 - $6.64 $4.54 Million - $7.03 Million	1,058,992 Added 546.39%	1,252,809 $6.31 Million
Q4 2021 Feb 14, 2022	SELL	$5.77 - $7.96 $795,815 - $1.1 Million	-137,923 Reduced 41.58%	193,817 $1.21 Million
Q3 2021 Nov 15, 2021	BUY	$6.67 - $9.8 $2.21 Million - $3.25 Million	331,740 New	331,740 $2.64 Million

Others Institutions Holding VXRT

# of Institutions

102

Shares Held

27.6M

Call Options Held

14.3K

Put Options Held

55.2K

View Full List

About Vaxart, Inc.

Ticker VXRT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 126,506,000
Market Cap $50.6M
Description
Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1...

More about VXRT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account